Guselkumab Modulates Differentially Expressed Genes in Blood of Patients With Psoriatic Arthritis: Results from Two Phase 3, Randomized, Placebo-Controlled Trials.
Stefan SiebertKristen M SweetChristopher T RitchlinElizabeth C HsiaAlexa P KollmeierXie L XuLoqmane SeridiQingxuan SongSheng GaoWarner ChenMichelle MironPublished in: ACR open rheumatology (2023)
These findings suggest a dysregulation of immune cell profiles in blood from patients in the baseline PsA cohort that approached levels in healthy controls after guselkumab treatment.
Keyphrases
- placebo controlled
- double blind
- end stage renal disease
- prostate cancer
- newly diagnosed
- phase iii
- chronic kidney disease
- phase ii
- open label
- clinical trial
- peritoneal dialysis
- prognostic factors
- squamous cell carcinoma
- genome wide
- study protocol
- randomized controlled trial
- gene expression
- radical prostatectomy
- radiation therapy
- dna methylation
- phase ii study